Pulmonary Artery Catheterization and Carvedilol Early Initiation in Cardiogenic SHOCK Due to HFrEF

ConditionsHeart Failure With Reduced Ejection Fraction Cardiogenic Shock

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age19+

SponsorMin-Seok Kim

About this trial

This study aims to compare the impact of hemodynamic monitoring using pulmonary artery catheter (PAC) on survival and inotropic agent reduction in patients with cardiogenic shock caused by heart failure with reduced ejection fraction (HFrEF). The investigators also intend to compare the difference in long-term survival rates among patients who have recovered from cardiogenic shock due to HFrEF, based on the timing of initiation of beta-blocker treatment.

Eligibility criteria

Qualifiers

Adults age 19 and above ( no age limit for elderly )

Patients with cardiogenic shock requiring intensive care monitoring in ICU

Patients eligible for oral medication administration

Patients who have provided research participation consent through a written informed consent form

Disqualifiers

Unwilling or unable to obtain informed consent by the participant or substitute decision maker

Patients with mechanical circulatory support at the time of screening

Patients with acute coronary syndrome

Patients with severe valvular heart disease requiring emergent percutaneous procedures or surgery

Trial design

Treatments tested in this trial

Pulmonary artery catheter

Treatment groups

160 Participants

are divided into 2 treatment groups

Sponsors and collaborators

Min-Seok Kim

Lead sponsor

Asan Medical Center

Sponsor institution

Source ClinicalTrials.gov